INDV-2000 First in Human

Indivior

Status and phase: Completed; Phase 1

Conditions: Opioid Dependence

Treatments: Drug: Placebo; Drug: INDV-2000

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT04413552

UG3DA050308 (U.S. NIH Grant/Contract)

INDV-2000-101

Details and patient eligibility

About

This study is a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD) of INDV-2000. After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction, single-dose study under fed and fasted conditions will be conducted.

Enrollment: 73 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Must be able to verbalize understanding the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures, and be able to comply with protocol requirements, rules and regulations of the study site, and be likely to complete all the study interventions.
• Must be considered a healthy male or non-childbearing female for Part I
• For Part II, must be a healthy male who did not participate in Part I and willing to consume a high-fat meal.
• Body mass index (BMI) within 18.0 to 30.0 kg/m^2, inclusive (minimum weight of at least 50.0 kg at Screening)
• Male subjects who are sexually active with female partners of child-bearing potential must use, with their partner, a condom plus an approved method of effective contraception from time of screening until 90 days after last dose of Investigational Medicinal Product (IMP). Additionally, male subjects must agree to not donate sperm during the study and for at least 90 days from last dose of IMP.

Exclusion criteria

• Have a medical history of clinically significant neurological, cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder as judged by an Investigator,
• Have clinically significant abnormal biochemistry, hematology or urinalysis results as judged by an Investigator,
• Have a history of narcolepsy or other significant sleep disorders
• Have disorders that may interfere with drug absorption, distribution, metabolism and excretion (ADME) processes,
• Positive test results for human immunodeficiency virus (HIV)-1/HIV-2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb).
• Serious cardiac illness or other medical condition including, but not limited to: Uncontrolled arrhythmias; History of congestive heart failure (CHF); myocardial infarction < 6 months from receipt of first dose of IMP; uncontrolled symptomatic angina; corrected QT value (QTcF) > 450 msec for males and > 470 msec for females or history of prolonged QT syndrome; Have a blood pressure reading outside of the following range: systolic < 86 or > 149 mmHg; diastolic < 50 or > 94 mmHg
• Current active hepatic or biliary disease. Subjects with cholecystectomy < 90 days prior to screening.
• Regular alcohol consumption in males > 21 units per week and females > 14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).
• Positive test result for alcohol and/or drugs of abuse at screening or prior to the first IMP administration.
• Current smokers and those who have smoked within the last 90 days. Current users of e-cigarettes and nicotine replacement products, and those who have used these products within the last 90 days.
• Concurrent treatment or treatment with an investigational drug within 30 days prior to the first dose.
• Blood donation of approximately 500 mL within 56 days or plasma donation within 7 days of screening.
• Subjects who are taking, or have taken, any prescribed or over-the-counter drugs (other than 2 g per day acetaminophen, hormone replacement therapy, hormonal contraception) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis if considered not to interfere with the objectives of the study, as agreed by an Investigator and Sponsor's Medical Monitor.
• Any consumption of food or drink containing poppy seeds, grapefruit or Seville oranges within 7 days prior to the IMP administration
• Treatment with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) 3A4 within 30 days prior to first dose of IMP.
• Known allergy or hypersensitivity to IMP or its excipients.
• Any condition that, in the opinion of an Investigator, would interfere with evaluation of the IMP or interpretation of subject safety or study results.
• Affiliated with, or a family member of, site staff directly involved in the study, or anyone with a financial interest in the outcome of the study.
• Subjects who are unable, in the opinion of an Investigator, to comply fully with the study requirements.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

73 participants in 3 patient groups, including a placebo group

Part I: INDV-2000

Experimental group

Description:

Participants will receive a single dose of INDV-2000. The starting dose is 1 mg with dose escalation dependent upon observed clinical safety, tolerability and pharmacokinetics.

Treatment:

Drug: INDV-2000

Part I: Placebo

Placebo Comparator group

Description:

Participants will receive a single dose of matching placebo.

Treatment:

Drug: Placebo

Part II: INDV-2000 Fasted/Fed

Experimental group

Description:

Participants will receive a single dose of INDV-2000 orally on Day 1 under fasted conditions and a single dose of INDV-2000 after a high-fat breakfast on Day 8. Dose to be determined based on a well-tolerated dose studied in Part I.

Treatment:

Drug: INDV-2000